Literature DB >> 30051202

Reproductive health care across the lifecourse of the female cancer patient.

Lisa A Rubinsak1, Mindy S Christianson2, Aletha Akers3, Jeanne Carter4, Andrew M Kaunitz5, Sarah M Temkin6.   

Abstract

Reproductive health is a key component of cancer care and survivorship, encompassing gynecologic issues ranging from contraception and fertility to treatment of sexual dysfunction and menopause. Yet, oncology providers are often unfamiliar with the management of gynecologic issues. In order to address the unmet needs of female cancer patients, reproductive health should be addressed at the time of cancer diagnosis and continue through survivorship. Universal screening for pregnancy intention can guide counseling on contraception and fertility preservation. Safe and efficacious contraceptive options for both patients undergoing active treatment and cancer survivors are available and can often offer non-contraceptive benefits such as regulation of menses. Prompt referral to reproductive endocrinology specialists allows patients to explore options for fertility preservation prior to the receipt of cancer-directed therapies. Due to a rapid drop in hormone levels, treatment-induced menopause often results in severe symptoms. In patients with induced menopause, balancing the risks of hormone therapy compared to the decreased quality of life and health concerns associated with early menopause may help patients with difficult decisions regarding symptom control. Cancer treatment impacts sexual function with both physical changes to the vulvovaginal tissues and altered relationship dynamics. Open discussions on the impact to sexual health are paramount to quality of life after cancer. While more data is needed in many areas, proactive management of reproductive health issues is crucial to quality of life in cancer survivorship. In this article, we review contemporary management of the reproductive health of the female cancer patient.

Entities:  

Keywords:  Cancer survivorship; Reproductive health

Mesh:

Year:  2018        PMID: 30051202     DOI: 10.1007/s00520-018-4360-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  66 in total

Review 1.  Long-Acting Reversible Contraception.

Authors:  Kathryn M Curtis; Jeffrey F Peipert
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

2.  Use of systemic hormone therapy in BRCA mutation carriers.

Authors:  Susan Domchek; Andrew M Kaunitz
Journal:  Menopause       Date:  2016-09       Impact factor: 2.953

3.  Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Shrujal Baxi; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Elizabeth Kvale; Robin M Lally; Terry S Langbaum; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Deborah A Freedman-Cass; Nicole R McMillian
Journal:  J Natl Compr Canc Netw       Date:  2017-09       Impact factor: 11.908

Review 4.  Progestin-only contraception and thromboembolism: A systematic review.

Authors:  Naomi K Tepper; Maura K Whiteman; Polly A Marchbanks; Andra H James; Kathryn M Curtis
Journal:  Contraception       Date:  2016-05-03       Impact factor: 3.375

5.  Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).

Authors:  Debra L Barton; Jeff A Sloan; Lynne T Shuster; Paula Gill; Patricia Griffin; Kathleen Flynn; Shelby A Terstriep; Fauzia N Rana; Travis Dockter; Pamela J Atherton; Michaela Tsai; Keren Sturtz; Jacqueline M Lafky; Mike Riepl; Jacqueline Thielen; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2017-09-18       Impact factor: 3.603

6.  Cancer and contraception. Release date May 2012. SFP Guideline #20121.

Authors:  Ashlesha Patel; E Bimla Schwarz
Journal:  Contraception       Date:  2012-06-07       Impact factor: 3.375

7.  Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.

Authors:  J Donnez; M M Dolmans; D Demylle; P Jadoul; C Pirard; J Squifflet; B Martinez-Madrid; A van Langendonckt
Journal:  Lancet       Date:  2004 Oct 16-22       Impact factor: 79.321

Review 8.  The effects of Implanon on menstrual bleeding patterns.

Authors:  Diana Mansour; Tjeerd Korver; Maya Marintcheva-Petrova; Ian S Fraser
Journal:  Eur J Contracept Reprod Health Care       Date:  2008-06       Impact factor: 1.848

9.  Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.

Authors:  Annica Bergendal; Helle Kieler; Anders Sundström; Angelica Lindén Hirschberg; Ljiljana Kocoska-Maras
Journal:  Menopause       Date:  2016-06       Impact factor: 2.953

10.  Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy.

Authors:  A Benshushan; N Rojansky; M Chaviv; S Arbel-Alon; A Benmeir; T Imbar; A Brzezinski
Journal:  Climacteric       Date:  2009-10       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.